OVID
Price
$0.32
Change
+$0.01 (+3.23%)
Updated
Jun 6 closing price
Capitalization
22.12M
70 days until earnings call
SYRE
Price
$16.97
Change
+$0.35 (+2.11%)
Updated
Jun 6 closing price
Capitalization
1B
52 days until earnings call
Interact to see
Advertisement

OVID vs SYRE

Header iconOVID vs SYRE Comparison
Open Charts OVID vs SYREBanner chart's image
Ovid Therapeutics
Price$0.32
Change+$0.01 (+3.23%)
Volume$941.04K
Capitalization22.12M
Spyre Therapeutics
Price$16.97
Change+$0.35 (+2.11%)
Volume$309.21K
Capitalization1B
OVID vs SYRE Comparison Chart
Loading...
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
OVID vs. SYRE commentary
Jun 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is OVID is a Buy and SYRE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 09, 2025
Stock price -- (OVID: $0.29 vs. SYRE: $15.08)
Brand notoriety: OVID and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: OVID: 182% vs. SYRE: 105%
Market capitalization -- OVID: $22.12M vs. SYRE: $1B
OVID [@Biotechnology] is valued at $22.12M. SYRE’s [@Biotechnology] market capitalization is $1B. The market cap for tickers in the [@Biotechnology] industry ranges from $323.27B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

OVID’s FA Score shows that 1 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • OVID’s FA Score: 1 green, 4 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, OVID is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

OVID’s TA Score shows that 3 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • OVID’s TA Score: 3 bullish, 1 bearish.
  • SYRE’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, OVID is a better buy in the short-term than SYRE.

Price Growth

OVID (@Biotechnology) experienced а +1.79% price change this week, while SYRE (@Biotechnology) price change was +2.03% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.11%. For the same industry, the average monthly price growth was +10.01%, and the average quarterly price growth was -2.16%.

Reported Earning Dates

OVID is expected to report earnings on Aug 18, 2025.

SYRE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+4.11% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($1B) has a higher market cap than OVID($22.1M). SYRE YTD gains are higher at: -35.223 vs. OVID (-68.855). OVID has higher annual earnings (EBITDA): -61.27M vs. SYRE (-208.57M). SYRE has more cash in the bank: 603M vs. OVID (53.1M). SYRE has less debt than OVID: SYRE (0) vs OVID (14.8M). OVID has higher revenues than SYRE: OVID (566K) vs SYRE (0).
OVIDSYREOVID / SYRE
Capitalization22.1M1B2%
EBITDA-61.27M-208.57M29%
Gain YTD-68.855-35.223195%
P/E RatioN/A1.68-
Revenue566K0-
Total Cash53.1M603M9%
Total Debt14.8M0-
FUNDAMENTALS RATINGS
OVID vs SYRE: Fundamental Ratings
OVID
SYRE
OUTLOOK RATING
1..100
5479
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
76
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
9565
P/E GROWTH RATING
1..100
9382
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OVID's Valuation (27) in the Pharmaceuticals Major industry is somewhat better than the same rating for SYRE (76). This means that OVID’s stock grew somewhat faster than SYRE’s over the last 12 months.

OVID's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as SYRE (100). This means that OVID’s stock grew similarly to SYRE’s over the last 12 months.

OVID's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as SYRE (98). This means that OVID’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's Price Growth Rating (65) in the Pharmaceuticals Major industry is in the same range as OVID (95). This means that SYRE’s stock grew similarly to OVID’s over the last 12 months.

SYRE's P/E Growth Rating (82) in the Pharmaceuticals Major industry is in the same range as OVID (93). This means that SYRE’s stock grew similarly to OVID’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
OVIDSYRE
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 12 days ago
84%
Bearish Trend 12 days ago
88%
Momentum
ODDS (%)
Bullish Trend 12 days ago
77%
Bullish Trend 12 days ago
80%
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bullish Trend 12 days ago
79%
Bearish Trend 12 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 12 days ago
85%
Bullish Trend 12 days ago
83%
Advances
ODDS (%)
Bullish Trend 25 days ago
74%
Bullish Trend 28 days ago
84%
Declines
ODDS (%)
Bearish Trend 19 days ago
88%
Bearish Trend 13 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 13 days ago
90%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AAPL200.420.21
+0.10%
Apple
SPY587.73-3.42
-0.58%
SPDR® S&P 500® ETF
BTC.X107802.330000-1192.312500
-1.09%
Bitcoin cryptocurrency
TSLA356.90-5.99
-1.65%
Tesla
GME31.21-3.80
-10.85%
GameStop Corp

OVID and

Correlation & Price change

A.I.dvisor indicates that over the last year, OVID has been closely correlated with JBIO. These tickers have moved in lockstep 79% of the time. This A.I.-generated data suggests there is a high statistical probability that if OVID jumps, then JBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OVID
1D Price
Change %
OVID100%
-0.21%
JBIO - OVID
79%
Closely correlated
-1.63%
SYRE - OVID
45%
Loosely correlated
+0.60%
KPRX - OVID
39%
Loosely correlated
+1.35%
NRIX - OVID
37%
Loosely correlated
+2.76%
NAUT - OVID
37%
Loosely correlated
-3.95%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with BEAM. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+0.60%
BEAM - SYRE
56%
Loosely correlated
-0.88%
APGE - SYRE
53%
Loosely correlated
-1.30%
IMNM - SYRE
52%
Loosely correlated
+0.35%
CGON - SYRE
52%
Loosely correlated
-0.94%
XNCR - SYRE
52%
Loosely correlated
-2.58%
More